Biovenic's Tech Goes Veterinary
For the past two decades, CAR therapies have revolutionized human oncology. Meanwhile, similar strategies in veterinary medicine have taken hold. Biovenic is changing that narrative by providing tailored solutions—veterinary CAR-T therapydevelopment—to tackle challenges in developing immune cell therapies for veterinary use.
Canine Osteosarcoma: Contemporary Guidance for Veterinary Practitioners
Canine osteosarcoma (OSA) is a common and aggressive bone tumor. Current best practices emphasize limb amputation combined with adjuvant chemotherapy, while emerging treatments like immunotherapy show promise. This comprehensive guideline provides veterinarians with expert recommendations to optimize care, improve survival, and maintain quality of life for affected dogs.
Environmental Chemical Exposures in Boxer Dogs With Multicentric Lymphoma
A prospective case-control study published in the Journal of Veterinary Internal Medicine has identified a significant association between exposure to the volatile organic compound (VOC) benzene and the development of multicentric lymphoma (ML) in Boxer dogs. The study moves beyond epidemiological questionnaires by using direct biomonitoring, providing some of the most compelling evidence to date that an environmental chemical is linked to oncogenesis in veterinary patients.
Why Most Dogs with Bladder Cancer Are Euthanized: A Revealing Study Sheds Light
Involving 59 dogs diagnosed with UC, this retrospective study scrutinized the clinical signs and circumstances surrounding euthanasia after treatments like radiation therapy and chemotherapy. The results were telling: the median survival time for these canine patients was just under a year. Astonishingly, 85% of these dogs were euthanized due to complications directly related to their cancer, with a staggering 62% suffering from local tumor progression leading to complete or partial urinary obstruction.
Revolutionary Cancer Treatment for Cats Leaves Vets Astonished
In the realm of veterinary medicine, a groundbreaking approach has emerged, offering new hope in the fight against one of the most daunting adversaries: feline cancer. Specifically, basal cell tumors, including the common basal cell carcinomas and the rarer basosquamous carcinomas found on or near the nasal planum in cats, have met their match with electrochemotherapy (ECT), including a novel method known as calcium electroporation. This cutting-edge treatment has been successfully deployed in managing these malignancies in three cats, marking a significant breakthrough in veterinary oncology.
Is This the Breakthrough Cure for Dog Cancer We've Been Waiting For? Cornell's New Study Sparks Hope
In a groundbreaking trial that's catching the eyes of pet owners and veterinarians alike, the Cornell University Hospital for Animals (CUHA) is on the brink of a medical breakthrough that could change the way we treat one of the most aggressive cancers in dogs: oral squamous cell carcinoma (OSCC). This cancer, notorious for its rapid progression and devastating impact on dogs' jaws and overall health, might finally meet its match in a new drug treatment that promises to be less invasive and more hopeful than the current, often disheartening surgical options.